Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

The Advantage Of Investing In Penny Stocks 2016

|Includes: CTRV, FBEC Worldwide, Inc. (FBEC), TOF

As with any type of investment, there can be a number of advantages as well as disadvantages to investing your money with a company or buying shares. ... The major benefit of Penny Stocks is that their Per Share Price is very low. There is no need of large capital to start investment. Here's a look at 3 companies that are budget friendly for those looking to make potential gains off of minimal investments, FBEC Worldwide Inc (OTCPK:FBEC), Tofutti Brands Inc.(NYSEMKT:TOF), and ContraVir Pharmaceuticals Inc (NASDAQ:CTRV).

FBEC Worldwide Inc (OTCMKTS:) formerly Frontier Beverage Company, Inc., is engaged in the sale of hemp-based energy products. The Company operates sales, distribution, and marketing business for the promotion and sale of hemp-based energy drinks. In the company's last press release announced that the company is in the process of change the name of the company from FBEC Worldwide, Inc. to Healthy Hemp Energy Co. In the past 3 moths the company has seen an increase of 360.31%.

Tofutti Brands Inc.(NYSEMKT:) is engaged in the development, production and marketing of TOFUTTI brand non-dairy frozen desserts and other food products. TOFUTTI products are soy-based, non-dairy products, which contain no butterfat, cholesterol or lactose. The Company operates through the segment of development, production, and marketing of soy-based, non-dairy frozen desserts, frozen food products, and soy-based cheese products. I the companys most recent news they announced that its Board of Directors has commenced a review of its strategic alternatives intended to enhance shareholder value. During the past few trading sessions the company has had a spike in trading 13.3%.

ContraVir Pharmaceuticals Inc (NASDAQ:) is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which includes CMX157 and CRV431. I the past 30 days the company has had an increase in trading price by 82.8%.